Obesity and the kidney: mechanistic links and therapeutic advances
Obesity is strongly associated with the development of diabetes mellitus and chronic kidney
disease (CKD), but there is evidence for a bidirectional relationship wherein the kidney also …
disease (CKD), but there is evidence for a bidirectional relationship wherein the kidney also …
Opportunities to optimize lifestyle interventions in combination with glucagon‐like peptide‐1‐based therapy
S Dash - Diabetes, Obesity and Metabolism, 2024 - Wiley Online Library
Obesity is a chronic multi‐system disease and major driver of type 2 diabetes and
cardiometabolic disease. Nutritional interventions form the cornerstone of obesity and type 2 …
cardiometabolic disease. Nutritional interventions form the cornerstone of obesity and type 2 …
PCSK7: A novel regulator of apolipoprotein B and a potential target against non-alcoholic fatty liver disease
V Sachan, M Le Dévéhat, A Roubtsova, R Essalmani… - Metabolism, 2024 - Elsevier
Background Epidemiological evidence links the proprotein convertase subtilisin/kexin 7
(PCSK7) to triglyceride (TG) metabolism. We associated the known PCSK7 gain-of-function …
(PCSK7) to triglyceride (TG) metabolism. We associated the known PCSK7 gain-of-function …
GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes: Pleiotropic Cardiometabolic Effects and Add-on Value of a Combined Therapy
AJ Scheen - Drugs, 2024 - Springer
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2
inhibitors (SGLT2is) have proven efficacy and safety in randomized clinical trials and …
inhibitors (SGLT2is) have proven efficacy and safety in randomized clinical trials and …
Semaglutide for the prevention of atrial fibrillation: a systematic review and meta-analysis
HD Zhang, L Ding, K Liu, LJ Mi, AK Zhang… - Diabetes & Metabolic …, 2024 - Elsevier
Background Semaglutide, a glucagon-like peptide-1 receptor agonist, is reported to have
cardiac benefits, but its effects on preventing atrial fibrillation (AF) remain inconclusive. This …
cardiac benefits, but its effects on preventing atrial fibrillation (AF) remain inconclusive. This …
[PDF][PDF] Clinical Research & Reviews
XX Yan, FH Peng, YJ Shen, M Tang - Diabetes & Metabolic …, 2024 - researchgate.net
Background: Semaglutide, a glucagon-like peptide-1 receptor agonist, is reported to have
cardiac benefits, but its effects on preventing atrial fibrillation (AF) remain inconclusive. This …
cardiac benefits, but its effects on preventing atrial fibrillation (AF) remain inconclusive. This …
The novel non-canonical roles of PCSK7
V Sachan - 2024 - escholarship.mcgill.ca
Background: The widely expressed proprotein convertase 7 (PCSK7) is the 7th member of
the secretory basic-amino-acid-specific subtilisin/kexin-like proprotein convertases (PCs or …
the secretory basic-amino-acid-specific subtilisin/kexin-like proprotein convertases (PCs or …